Europe Drug Delivery Market Size, Share, Opportunities, And Trends By Type (Inhalation Drug Delivery, Injectable Drug Delivery, Nasal Drug Delivery, Oral Drug Delivery, Transdermal Drug Delivery), By Application (Treatment of Diseases, Research/Academic Purposes), And By Geography - Forecasts From 2025 To 2030

Europe Drug Delivery Market Size:

The European Drug Delivery Market, valued at US$253.649 billion in 2025, is projected to grow at a CAGR of 5.08%, reaching a market size of US$342.982 billion by 2030.

Increasing public spending on healthcare, expanding research and development, advancing technology, growing age-related diseases, and rising prevalence of chronic diseases are some drivers for the European drug delivery market. Growing biologics markets are also the key contributor to the market’s expansion.

Europe Drug Delivery Market Overview & Scope:

Europe’s Drug Delivery market is segmented by:

• Type: The European drug delivery market is segmented into Inhalation drug delivery, injectable drug delivery, nasal drug delivery, oral drug delivery, transdermal drug delivery, and others.
• Application: The market is segmented into treatment of diseases and Research/academic purposes.
• Region: The European drug delivery market is segmented into the U.K., Germany, Switzerland, France, Spain, Italy, and Others.

Top Trends Shaping the Europe Drug Delivery Market:

1. Rise in nanoparticle drug delivery

• There are growing advancements in nanotechnology in the European drug delivery market for its efficiency in targeted drug delivery, whose demand is growing due to rising chronic diseases.

2. Integration of artificial intelligence

• There is a shift towards the integration of artificial intelligence and machine learning in drug delivery, revolutionizing patient care by enhancing data analysis and prediction. Large datasets, including patient information and medication interactions, may be analyzed by AI-powered algorithms to anticipate appropriate dosage regimens and personalized treatment plans. The fast advancement of AI and ML technologies has opened up new avenues for medication delivery. For instance, Genentech, a member of Roche Group, has leveraged AI and ML to redefine the drug discovery process through “The lab in a loop” mechanism, integrating generative AI into drug discovery and development.

Europe Drug Delivery Market Growth Drivers vs. Challenges:

Opportunities:

• Increase in Chronic and Infectious Diseases: The increase in chronic and infectious diseases is one of the primary drivers of the European drug delivery market. In addition to Europe’s Cancer Beating Plan, the European Commission is also working on the key areas of cardiovascular diseases, diabetes, mental health, neurological disorders, and chronic respiratory diseases that are the major causes of death. The increasing number of chronic diseases has given rise to a new delivery system, CRDDS (Controlled Release Drug Delivery System), a reliable method that uses an appropriate amount of drug dosage and releases it in a predetermined area.

Infectious diseases have witnessed a sudden outbreak and are emerging at a rate never seen before. In the last 5-6 decades, the world has witnessed contagious diseases like SARS, Ebola, Swine Flu, MERS, Zika, chikungunya, and COVID-19, raising the need to introduce more disease-specific drugs to the market. With history kept in mind, the outbreak of diseases in the future needs to be overpowered by a strong drug-delivering market in the coming years.

• Rising aging population: The rising aging population of Europe will be a major factor driving the demand for the development of the drug delivery market in Europe. Europe is home to the largest aging population, with 90.5 million people aged above 65 years in 2019, which is estimated to reach 129.8 million by 2050, as per the data by Eurostat. During this period, the number of people in the EU-27 aged 75-84 years is projected to expand by 56.1 %, while the number aged 65-74 years is projected to increase by 16.6 %. The rising aging population is driving the demand for healthcare, leading to market growth in the drug delivery market in Europe.
• Increasing investment in research and development: Increasing research and development investments for drug delivery are expected to be a significant driver for the industry in the forecast period. Although it is a time-consuming and costly process, it is expected to be crucial in the development of the European drug market. Companies like Pfizer, Bayer AG, etc., are known to have been engaged in severe research projects and, thus, have added substantially to the scientific knowledge and medical technology advancements in the drug market.

Challenges:

• High cost for research and development:  The cost of research and development is high. The high manufacturing cost leads to the high cost of drug delivery, acting as a major restraint for the European Drug Delivery market.

Europe Drug Delivery Market Regional Analysis:

• Germany: Germany has a significant share in the drug delivery market due to high investment in research and development along with the presence of some of the major companies in the market. It is advancing in some of the segments of drug delivery, such as nanomedicine research, driving the growing trend of nanotechnology. As per the Germany Trade and Invest data, nanotechnology is among the nation’s most innovative technology sectors. Its nanotechnology R&D expenditure amounts to 10% of total turnover, with approximately half of the nanotechnology companies in Europe from Germany, highlighting the pioneering of Germany in the European drug delivery market.
• U.K: The U.K. is projected to hold a significant market share in the European drug delivery market due to the presence of top pharma companies, driving innovation. The rising research and development in the pharmaceutical market is also propelling the market’s expansion.  

Europe Drug Delivery Market Competitive Landscape:

The market is consolidated, with the presence of some of the leading players such as Bayer, Becton, Dickinson Company, GlaxoSmithKline, Novartis, and Roche Holdings. They have a strong market presence in the drug delivery market. The market strategies of the players include:

• Product Development and approval: The European Medicines Agency has approved Vabysmo® (faricimab) 6.0 mg single-dose prefilled syringe (PFS) for use in the treatment of neovascular or ‘wet’ age-related macular degeneration (nAMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO). This will allow easy administration in people for ophthalmologists
• Research and Development: In January 2025, BioNxt, a company specializing in advanced drug delivery systems, accelerates R&D by establishing a new laboratory facility in Gen-Plus Contract Research and Development Organization (CRDO) in Munich, Germany, with operations scheduled to begin on March 1, 2025. It will accelerate the company’s research, including drug delivery systems.

Europe Drug Delivery Market Scope:

Report Metric	Details
Europe Drug Delivery Market Size in 2025	US$253.649 billion
Europe Drug Delivery Market Size in 2030	US$342.982 billion
Growth Rate	CAGR of 5.08%
Study Period	2020 to 2030
Historical Data	2020 to 2023
Base Year	2024
Forecast Period	2025 – 2030
Forecast Unit (Value)	USD Million
Segmentation	Type Application Geography
Geographical Segmentation	U.K., Germany, Switzerland, France, Spain, Italy, Others
List of Major Companies in Europe Drug Delivery Market	Ascendis Pharma A/S Pfizer Inc. Becton, Dickinson Company Baxter International Inc. Novartis
Customization Scope	Free report customization with purchase

 

Europe Drug Delivery Market is analyzed into the following segments:

By Type

• Inhalation Drug Delivery
• Injectable Drug Delivery
• Nasal Drug Delivery
• Oral Drug Delivery
• Transdermal Drug Delivery

By Application

• Treatment of diseases
• Research/Academic purposes

By Region

• U.K.
• Germany
• Switzerland
• France
• Spain
• Italy
• Others

Our Best-Performing Industry Reports:

• Biosimulation Market
• Biomimetic Materials Market
• Genomic Biomarkers Market

---

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base and Forecast Years Timeline

1.8. Key benefits for the stakeholders

2. RESEARCH METHODOLOGY

2.1. Research Design

2.2. Research Process

3. EXECUTIVE SUMMARY

3.1. Key Findings

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

4.5. Analyst View

5. EUROPE DRUG DELIVERY MARKET BY TYPE

5.1. Introduction

5.2. Inhalation Drug Delivery

5.3. Injectable Drug Delivery

5.4. Nasal Drug Delivery

5.5. Oral Drug Delivery

5.6. Transdermal Drug Delivery

5.7. Others

6. EUROPE DRUG DELIVERY MARKET BY APPLICATION

6.1. Introduction

6.2. Treatment of diseases

6.3. Research/Academic purposes

7. EUROPE DRUG DELIVERY MARKET BY GEOGRAPHY

7.1. Introduction

7.2. U.K.

7.2.1. By Type

7.2.2. By Application

7.3. Germany

7.3.1. By Type

7.3.2. By Application

7.4. Switzerland

7.4.1. By Type

7.4.2. By Application

7.5. France

7.5.1. By Type

7.5.2. By Application

7.6. Spain

7.6.1. By Type

7.6.2. By Application

7.7. Italy

7.7.1. By Type

7.7.2. By Application

7.8. Others

7.8.1. By Type

7.8.2. By Application

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

8.1. Major Players and Strategy Analysis

8.2. Market Share Analysis

8.3. Mergers, Acquisitions, Agreements, and Collaborations

8.4. Competitive Dashboard

9. COMPANY PROFILES

9.1. Ascendis Pharma A/S

9.2. Pfizer Inc.

9.3. Becton, Dickinson Company

9.4. Baxter International Inc.

9.5. Novartis

9.6. Bayer AG

9.7. Antares Pharma

9.8. Roche Holding

9.9. Novo Nordisk

9.10. GlaxoSmithKline

10. APPENDIX

10.1. Currency 

10.2. Assumptions

10.3. Base and Forecast Years Timeline

10.4. Key Benefits for the Stakeholders

10.5. Research Methodology 

10.6. Abbreviations 

Ascendis Pharma A/S

Pfizer Inc.

Becton, Dickinson Company

Baxter International Inc.

Novartis

Bayer AG

Antares Pharma

Roche Holding

Novo Nordisk

GlaxoSmithKline